Project Grant R01DK149096
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $632K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of California, Los Angeles $128,235 on September 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to discover mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) through single nucleus RNA-sequencing analysis of cell-type and cellular subtypes in subcutaneous adipose tissue, visceral adipose...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Texas Southwestern Medical Center $694,250 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to explore a novel pathway for ApoB mRNA degradation in regulating VLDL secretion and steatotic liver disease. The recipient will conduct basic biomedical research identifying mechanisms by which the HELZ2 gene regulates hepatic lipid secretion...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Beth Israel Deaconess Medical Center $164,484 on August 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of DNAJC22 in metabolic dysfunction-associated steatotic liver disease (MASLD). The award funds research exploring DNAJC22, a gene of unknown function identified through genome-wide CRISPR-Cas9 screening and human genetic association studies...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pennsylvania $789,828 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop theoretical models validated through experiments explaining the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). The project develops and validates tissue-mechanics models to predict how cholesterol crystals in the liver drive...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Mayo Clinic $495,130 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate autophagic processes and hepatocellular steatosis. The award funds research into the mechanisms by which hepatocytes regulate lipid droplet storage, breakdown, and catabolism in metabolic dysfunction-associated steatotic liver disease (MASLD). The research focuses on two...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Regents of the University of California, San Francisco $194,076 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds a multi-omic investigation of the gut-liver axis in HIV-related liver disease. The project will define mechanistic and biomarker pathways along the gut-liver axis that contribute to and predict hepatic fibrosis in people...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Scripps Research Institute $152,600 on February 15, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research examining how hepatic endoplasmic reticulum (ER) stress affects the integrity of the secreted proteome, with focus on protein aggregation diseases including systemic amyloidoses. The research will use established and novel proteomics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $803,565 to the University of California, Davis on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and characterize an orally delivered nanodrug for metabolic disease treatment. The project targets metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus by addressing gut dysbiosis and restoring impaired signaling...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $814,500 to the University of Pittsburgh on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to fund research dissecting functional decompensation of end-stage liver disease and investigating the mechanism and impact of transcription factors on long-term functional reprogramming. The research examines how the transcription factor HNF4A—which controls...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pennsylvania $892,491 on February 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate acetyl-CoA metabolism and the regulation of hepatic lipid homeostasis in metabolic dysfunction-associated steatotic liver disease (MASLD). The research applies spatio-temporal lipidomics, flux analysis, and gene expression analysis to explore how...